
    
      This study is designed as a pivotal study to compare the safety and efficacy of a selected
      dose regimen of somavaratan to daily rhGH. The study is a randomized, multi-center, open
      label study of 12 months duration. The primary endpoint is height velocity at 12 months.
    
  